论文部分内容阅读
目的:探讨凝结芽孢杆菌活菌片对3岁以下小儿反复呼吸道感染预防效果。方法:选取2014年6月至2015年12月鹤壁市人民医院儿科门诊和住院部收治的反复呼吸道感染患儿276例,随机分为研究组、对照组,每组各138例。研究组患儿口服凝结芽孢杆菌活菌片2个月,对照组患儿给予免疫调节剂治疗2个月,停药后对两组患儿行为期6个月的随访,记录呼吸道感染频率,喘息、发热、咳嗽时间,以及抗生素使用和不良反应发生情况。结果:第4个月起,研究组中发热、咳嗽、喘息的发生率明显低于对照组;第6个月研究组中呼吸道感染发生率明显低于对照组;差异均有统计学意义(P<0.05)。研究组患儿累计呼吸道感染、发热、咳嗽、喘息的发生率明显低于对照组,差异有统计学意义(P<0.05)。第3个月时两组中呼吸道感染、发热、咳嗽、喘息的发生率之间差异无统计学意义(P>0.05);研究组发热、咳嗽持续时间明显短于对照组,差异有统计学意义(P<0.05)。第3个月起研究组抗生素使用率明显低于对照组,差异有统计学意义(P<0.05);研究期间,两组患儿均未出现药物不良反应。结论:凝结芽孢杆菌活菌片可有效降低反复呼吸道感染发生率,缩短症状持续时间,减少抗生素的使用。
Objective: To investigate the preventive effect of Bacillus coagulans viable bacterium tablets on recurrent respiratory tract infections in children under 3 years of age. Methods: A total of 276 children with recurrent respiratory tract infections admitted to pediatric outpatient department and inpatient department of Hebi Municipal People’s Hospital from June 2014 to December 2015 were randomly divided into study group and control group, with 138 cases in each group. The study group oral live B. coagulans live bacteria tablets for 2 months, the control group of children given immunomodulator for 2 months, two groups of children after stopping the behavioral period of 6 months of follow-up, record the frequency of respiratory infections, wheezing , Fever, cough time, and the use of antibiotics and adverse reactions. Results: From the fourth month, the incidence of fever, cough and wheeze in the study group was significantly lower than that in the control group. The incidence of respiratory tract infection in the study group at the 6th month was significantly lower than that of the control group (P <0.05). The cumulative incidence of respiratory tract infection, fever, cough and wheeze in study group was significantly lower than that in control group, with statistical significance (P <0.05). There was no significant difference in the incidence of respiratory tract infection, fever, cough and wheeze between the two groups at the third month (P> 0.05). The duration of fever and cough in the study group was significantly shorter than that in the control group (P <0.05). The antibiotic utilization rate in the study group from the third month was significantly lower than that in the control group (P <0.05). During the study period, no adverse drug reactions occurred in both groups. CONCLUSION: Bacillus coagulans active bacterium tablets can effectively reduce the incidence of recurrent respiratory tract infections, shorten the duration of symptoms and reduce the use of antibiotics.